Related references
Note: Only part of the references are listed.Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Merryn Voysey et al.
LANCET (2021)
Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders
Andrea Calcagno et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Development and validation of the first point-of-care assay to objectively monitor adherence to HIV treatment and prevention in real-time in routine settings
Monica Gandhi et al.
AIDS (2020)
Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial
Dirk Schuermann et al.
LANCET HIV (2020)
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial
Raphael J. Landovitz et al.
LANCET HIV (2020)
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
Kenneth H Mayer et al.
LANCET (2020)
Clinical targeting of HIV capsid protein with a long-acting small molecule
John O. Link et al.
NATURE (2020)
Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial
Elizabeth R. Brown et al.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (2020)
Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men
Eugenie Shieh et al.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (2019)
Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis
D. R. Tait et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Prevention of M-tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination
E. Nemes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette–Guérin vaccination against tuberculosis
I Abubakar et al.
HEALTH TECHNOLOGY ASSESSMENT (2014)
Share Paper
